The ESMO Congress 2026, taking place in Madrid from 23–27 October 2026, will bring together the international oncology community to present new clinical evidence, emerging therapeutic approaches, advances in cancer research and developments in patient care.
For oncology professionals, the challenge is not simply keeping pace with the volume of new evidence. It is understanding which findings matter, how robust the evidence is, where they may change clinical decisions, and how they can be applied in real-world practice.
Best of ESMO 2026 is designed around this need.
FROM DATA TO DECISION
The value of new oncology evidence lies not only in the results themselves, but in understanding what those results mean for patients and clinical practice.
Best of ESMO 2026 will focus on:
Understanding the Evidence
Critical appraisal of major clinical trial findings, including
study design, endpoints, efficacy, safety and patient-reported
outcomes where relevant.
Interpreting Biomarkers
Exploring the growing role of molecular profiling, genomic
alterations, predictive biomarkers and liquid biopsy in
treatment selection and disease management.
Evaluating New Treatment Strategies
Examining developments in immunotherapy, antibody-drug
conjugates, targeted therapies and emerging therapeutic
platforms.
Understanding Sequencing & Clinical Integration
Discussing how new evidence may influence treatment pathways,
lines of therapy, combinations and sequencing across disease
settings.
Connecting Guidelines with Practice
Reviewing relevant updates in ESMO recommendations and
considering how evolving evidence influences clinical
decision-making.
Contextualising Global Evidence for India
Exploring questions of diagnostic availability, treatment
access, affordability, infrastructure and real-world
implementation within the Indian healthcare environment.
Multidisciplinary Clinical Discussion
Creating space for perspectives across medical, surgical and
radiation oncology, pathology, radiology, molecular diagnostics
and other disciplines involved in contemporary cancer care.
WHY IT MATTERS
Cancer care is evolving rapidly. New evidence is changing treatment strategies, biomarkers are reshaping patient selection, and emerging therapies are expanding the possibilities of personalised care.
Best of ESMO 2026 creates a dedicated space to move beyond what is new and examine what it means for clinical practice.
From the science presented in Madrid to the decisions made in clinics across India, the focus remains on translating evidence into meaningful clinical understanding.